Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | EP300 | Q09472 | 9/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3270929 | 0.93 | KDM1A (0.37) | FFAR4KDM1AEP300CDK2CHUK | |
| SCHEMBL31080672 | 0.89 | ATXN2 (0.41) | FFAR4KDM1AEP300PDE4D | |
| SCHEMBL7209219 | 0.83 | IDO1 (0.37) | CDK2 | |
| SCHEMBL31080336 | 0.79 | PDCD1 (0.40) | KDM1AEP300 | |
| SCHEMBL28032210 | 0.79 | EP300 (0.43) | FFAR4KDM1AEP300CDK2 | |
| SCHEMBL16333742 | 0.75 | DRD4 (0.46) | FFAR4KDM1AEP300CDK2 | |
| SCHEMBL29953895 | 0.75 | FFAR4 (0.40) | FFAR4KDM1AEP300 | |
| SCHEMBL28408353 | 0.74 | KDM1A (0.37) | KDM1AEP300 | |
| SCHEMBL4434419 | 0.73 | CDK2 (0.40) | CDK2 | |
| SCHEMBL3272778 | 0.73 | HTR6 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION | 2025-03-06 | — | — | US | disclosed |
| EP-4433470-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | Blueprint Medicines Corporation (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118265706-A | CDK2 inhibitors and methods of making and using the same | 缆图药品公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023092107-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023092088-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023092088-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| CN-107567443-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| EP-3239143-B1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEMICAL LTD (KR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| CN-101679266-A | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | CDK2, CDK20, CDK2AP1 | FFAR4 4857/4885KDM1A 1929/4885EP300 391/4885 |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | FFAR4 24/4885KDM1A 2451/4885EP300 1766/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | FFAR4 3898/4885KDM1A 1020/4885EP300 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.